Hormonal
Semaglutide, a GLP-1 receptor agonist, significantly reduces body weight and improves glycemic control in patients with type 2 diabetes and obesity through glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation.
Semaglutide is a prescription medication for T2DM and obesity that works by mimicking a gut hormone to regulate blood sugar, reduce appetite, and slow digestion. It is available as a weekly injection or a daily pill. Clinical trials show significant weight loss (4-15%) and improved blood sugar control (HbA1c reduction of 1.0-1.8%). Common side effects include nausea, which often improves over time. It is recommended for patients with cardiovascular risk.
By mimicking the endogenous incretin hormone GLP-1, semaglutide has a variety of physiological effects that help to improve metabolic control. It increases glucose-dependent insulin secretion while also reducing inappropriate appetite. Glucagon release, delayed gastric emptying, and increased satiety combine to produce better glycemic management and considerable weight reduction.
Why this rating
The paper cites large-scale clinical trials (SUSTAIN, PIONEER, STEP) and FDA approvals.
Source
Semaglutide: A Comprehensive Review of its Pharmacology, Clinical Applications, and Future Therapeutic Potential
Sitaram S. Pawar et al. · Journal of Drug Delivery and Therapeutics · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →